uniQure Raises $225M in Upsized Share Offering
Event summary
- uniQure priced a public offering of 4,945,055 ordinary shares at $45.50 per share, raising approximately $225 million.
- The offering was upsized from its initial announcement and includes an option for underwriters to purchase up to 741,758 additional shares within 30 days.
- The offering is expected to close on or about June 25, 2026, subject to customary closing conditions.
The big picture
uniQure's successful upsized offering underscores the continued investor interest in gene therapy companies with promising pipelines. The $225 million raise positions uniQure to accelerate its clinical programs and potentially expand its market presence, though it must navigate a highly competitive biotech landscape where execution risk remains high.
What we're watching
- Capital Deployment
- How uniQure will allocate the $225 million proceeds to advance its pipeline of gene therapies for Huntington's disease, refractory temporal lobe epilepsy, and Fabry disease.
- Market Conditions
- Whether the upsized offering reflects strong investor confidence in the gene therapy sector or a strategic move by uniQure to capitalize on favorable market conditions.
- Execution Risk
- The pace at which uniQure can translate its recent fundraising into tangible clinical and commercial milestones, given the competitive landscape of gene therapy development.
Related topics